BDBM703969 (R)-6-amino-7-methyl-N-(5,6,7,8- tetrahydroquinoxalin-5-yl)-N-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1,5-naphthyridine-3- carboxamide LCMS [M + 1]+ = 494.1 1H NMR (400 MHz, MeOD-d4) $#948; = 8.93-8.73 (m, 2H), 8.60-8.51 (m, 1H), 8.45-8.38 (m, 1H), 8.27- 8.05 (m, 2H), 7.92-7.83 (m, 1H), 7.82-7.72 (m, 1H), 5.32 (br dd, J = 6.0, 10.8 Hz, 1H), 5.02 (d, J = 16.4 Hz, 1H), 4.26 (d, J = 16.4 Hz, 1H), 3.09-2.83 (m, 2H), 2.39-::US20240368153, Example 10-6
SMILES Cc1cc2ncc(C(=O)N(Cc3ccc(C(F)(F)F)cn3)C3CCCc4nccnc43)cc2nc1N
InChI Key InChIKey=VSRTXQHVPZHROV-UHFFFAOYSA-N
Data 1 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 1 hit for monomerid = 703969
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 925nMAssay Description:Table B2: The assay uses recombinant full-length histone H2A as the PRMT5 substrate. Enzymatic transfer of the tritiated methyl group from S-adenosyl...More data for this Ligand-Target Pair
